🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Karyopharm Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, China, Ireland and India registers with Karyopharm Therapeutics as lead sponsor. Synced 26 Sep 2026
7Current trials
2Recruiting now
18Drugs in these trials
5Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Karyopharm Therapeutics is the lead sponsor of 7 current clinical trials in our USA, UK, China, Ireland and India registers. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Selinexor, Dexamethasone and Ruxolitinib. The most-studied condition is Myelofibrosis.

ClinicalTrials.gov trials by status

  • Recruiting229%
  • Active, closed571%

Trials by phase

  • Phase 2343%
  • Phase 3229%
  • Phase 1/2114%
  • Phase 2/3114%
01

Clinical trials sponsored by Karyopharm Therapeutics

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806 · ClinicalTrials.gov ↗ · Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Phase 2 Recruiting 2024-04 UK, USA
Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 1/2 Recruiting 2015-10 USA
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931 · ClinicalTrials.gov ↗ · Endometrial Cancer
Drug: Selinexor
Phase 3 Active, closed 2023-04 Ireland, USA
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
Drug: Selinexor
Phase 2 Active, closed 2014-11 UK, USA, India
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389 · ClinicalTrials.gov ↗ · Myelofibrosis
Phase 3 Active, closed 2021-03 UK, USA, China
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870 · ClinicalTrials.gov ↗ · Myelofibrosis
Drug: Selinexor
Phase 2 Active, closed 2021-03 USA, China
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2/3 Active, closed 2020-09 USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Karyopharm Therapeutics trials

18 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Karyopharm Therapeutics trials

7 conditions
Myelofibrosis3Endometrial Cancer1Moderate Thrombocytopenia1Mild Thrombocytopenia1Diffuse Large B-cell Lymphoma1Multiple Myeloma1Relapsed/Refractory Diffuse Large B-cell Lymphoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA72
Clinical trials in UK31
Clinical trials in China30
Clinical trials in Ireland10
Clinical trials in India10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Myelofibrosis

SponsorTrials
Chia Tai Tianqing Pharmaceutical Group5
Geron Corporation2
Sumitomo Pharma America1
Cellenkos1
Telios Pharma1

Sponsors with the most current trials registered for this condition.

06

Questions about Karyopharm Therapeutics trials

How many clinical trials does Karyopharm Therapeutics sponsor?

Karyopharm Therapeutics is the lead sponsor of 7 current trials on ClinicalTrials.gov in our USA, UK, China, Ireland and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Karyopharm Therapeutics trials recruiting?

Yes. 2 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Karyopharm Therapeutics testing?

Its current trials name 18 drugs and biologicals as interventions. The most frequent are Selinexor (7), Dexamethasone (2), Ruxolitinib (2), Belantamab mafodotin (1) and Bortezomib (1). The number in brackets is how many of its trials name each drug.

Does Karyopharm Therapeutics have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.